Investor Relations
Quarterly Reports
Fiscal year is June 1 - May 31
Fiscal Year 2021
- 1st Quarter, Conference Call, 10Q
- 2nd Quarter, Conference Call, 10Q
- 3rd Quarter, Conference Call, 10Q
- 4th Quarter, Conference Call, 10K
Fiscal Year 2020
- 1st Quarter, Conference Call, 10Q
- 2nd Quarter, Conference Call, 10Q
- 3rd Quarter, Conference Call, 10Q
- 4th Quarter, Conference Call, 10K
The Soleris Direct Yeast and Mold test was designed for the rapid detection of yeast and mold in various food, nutraceutical, and personal care/cosmetics products.
The split is the sixth in the company’s 39-year history, the most recent being a four-for-three stock split in December 2017.
NEOGEN’s new AccuPoint Advanced Next Generation (NG) system features a more modernized and user-friendly handheld device, with an easy-to-use ergonomic design.
Third quarter net income was $13,377,000, up 10% compared to the prior year’s $12,200,000.
Papesh joined NEOGEN’s Board in October 1993, and has helped guide the company from approximately $8 million in annual revenues to approximately $418 million in revenues in its most recently completed fiscal year (May 31).
NEOGEN’s Early Warning solution is a piloted, accurate, and reliable test to monitor for the presence of SARS-CoV-2, the virus known to cause COVID-19, in sludge from wastewater facilities.
Virtual Annual Shareholders’ Meeting: October 8 at 10:00 am ET
Play Back
Annual Reports
To learn more about what NEOGEN does, check out our Annual Report. NEOGEN’s Annual Report includes audited financial statements with additional perspective from our management team. The Form 10-K contains the audited financial statements, and also offers a comprehensive look at the overall business.
Previous Reports
Form 10-K
Additional Information
Contact Information
NEOGEN's Investor Relations
620 Lesher Place, Lansing, MI 48912
ir@NEOGEN.com
Shareholder Inquiries
Transfer Agent and Registrar
American Stock Transfer & Trust
59 Maiden Lane
New York, NY 10038
Get a stock quote on NEOGEN Corporation from NASDAQ.